Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
Historique:
received: 21 04 2020
revised: 19 07 2020
accepted: 16 08 2020
entrez: 21 12 2020
pubmed: 22 12 2020
medline: 1 7 2021
Statut: ppublish

Résumé

Phosphoglucomutase 1 deficiency is a congenital disorder of glycosylation (CDG) with multiorgan involvement affecting carbohydrate metabolism, N-glycosylation and energy production. The metabolic management consists of dietary D-galactose supplementation that ameliorates hypoglycemia, hepatic dysfunction, endocrine anomalies and growth delay. Previous studies suggest that D-galactose administration in juvenile patients leads to more significant and long-lasting effects, stressing the urge of neonatal diagnosis (0-6 months of age). Here, we detail the early clinical presentation of PGM1-CDG in eleven infantile patients, and applied the modified Beutler test for screening of PGM1-CDG in neonatal dried blood spots (DBSs). All eleven infants presented episodic hypoglycemia and elevated transaminases, along with cleft palate and growth delay (10/11), muscle involvement (8/11), neurologic involvement (5/11), cardiac defects (2/11). Standard dietary measures for suspected lactose intolerance in four patients prior to diagnosis led to worsening of hypoglycemia, hepatic failure and recurrent diarrhea, which resolved upon D-galactose supplementation. To investigate possible differences in early vs. late clinical presentation, we performed the first systematic literature review for PGM1-CDG, which highlighted respiratory and gastrointestinal symptoms as significantly more diagnosed in neonatal age. The modified Butler-test successfully identified PGM1-CDG in DBSs from seven patients, including for the first time Guthrie cards from newborn screening, confirming the possibility of future inclusion of PGM1-CDG in neonatal screening programs. In conclusion, severe infantile morbidity of PGM1-CDG due to delayed diagnosis could be prevented by raising awareness on its early presentation and by inclusion in newborn screening programs, enabling early treatments and galactose-based metabolic management.

Identifiants

pubmed: 33342467
pii: S1096-7192(20)30185-2
doi: 10.1016/j.ymgme.2020.08.003
pii:
doi:

Substances chimiques

PGM1 protein, human EC 5.4.2.2
Phosphoglucomutase EC 5.4.2.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-146

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Auteurs

Federica Conte (F)

Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Federica.Conte@radboudumc.nl.

Eva Morava (E)

Center of Individualized Medicine, Department of Clinical Genomics, Mayo Clinic, Rochester, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA. Electronic address: Morava-Kozicz.Eva@mayo.edu.

Nurulamin Abu Bakar (NA)

Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Nurulamin.BinAbuBakar@radboudumc.nl.

Saskia B Wortmann (SB)

Institute of Human Genetics, Technische Universität München, Munich, Germany; Institute of Human Genetics, Helmholtz Zentrum München, Munich, Germany; Department of Pediatrics, Salzburger Landeskliniken (SALK) und Paracelsus Medical University (PMU), Salzburg, Austria. Electronic address: wortmann-hagemann@helmholtz-muenchen.de.

Anne Jonge Poerink (AJ)

Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; Department of Pediatrics, Medisch Centrum Twente, Enschede, the Netherlands. Electronic address: A.JongePoerink@mst.nl.

Stephanie Grunewald (S)

Great Ormond Street Hospital Foundation Trust, UCL Institute of Child Health, London, Great Britain, UK. Electronic address: Stephanie.Grunewald@gosh.nhs.uk.

Ellen Crushell (E)

National Centre for Inherited Metabolic Disorders, Children's Health Ireland at Temple Street and Crumlin Hospitals, Dublin, Ireland. Electronic address: Ellen.Crushell@cuh.ie.

Lihadh Al-Gazali (L)

Department of Pediatrics, College of Medicine & Health Sciences, UAE University, Al-Ain, United Arab Emirates. Electronic address: l.algazali@uaeu.ac.ae.

Maaike C de Vries (MC)

Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. Electronic address: Maaike.deVries@radboudumc.nl.

Lars Mørkrid (L)

Institute of Clinical Medicine, University of Oslo, Norway; Department of Medical Biochemistry, Oslo University Hospital-Rikshospitalet, Norway. Electronic address: lamo2@ous-hf.no.

Jozef Hertecant (J)

Genetics and Metabolics Service, Tawam Hospital, Al Ain, United Arab Emirates. Electronic address: jhertecant@seha.ae.

Katja S Brocke Holmefjord (KS)

Department. of Pediatric Habilitation/Department of Pediatric Neurology, Stavanger University Hospital, Stavanger, Norway. Electronic address: katja.sara.brocke.holmefjord@sus.no.

David Kronn (D)

Medical Genetic, Inherited Metabolic Diseases and Lysosomal Storage Disorders Center, Boston Children Hospital, MA, USA. Electronic address: David_Kronn@bchphysicians.org.

Annette Feigenbaum (A)

Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, USA. Electronic address: afeigenbaum@ucsd.edu.

Ralph Fingerhut (R)

Swiss Newborn Screening Laboratory, Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Electronic address: Ralph.Fingerhut@kispi.uzh.ch.

Sunnie Y Wong (SY)

Hayard Genetics Center, Tulane University School of Medicine, New Orleans, LA, United States of America. Electronic address: swong1@tulane.edu.

Monique van Scherpenzeel (M)

Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; GlycoMScan B.V, Oss, the Netherlands. Electronic address: monique.vanscherpenzeel@glycomscan.com.

Nicol C Voermans (NC)

Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: Nicol.Voermans@radboudumc.nl.

Dirk J Lefeber (DJ)

Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Dirk.Lefeber@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH